Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
Abstract Background Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementatio...
Main Authors: | Ning Tang, Dan Lyu, Yan Zhang, Haiping Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | BMC Women's Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12905-017-0393-z |
Similar Items
-
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
by: Yuqiang Zhang, et al.
Published: (2021-06-01) -
Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study
by: Marina Piljić Burazer, et al.
Published: (2019-09-01) -
Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
by: Haiguang Zhang, et al.
Published: (2017-04-01) -
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer — a pilot study
by: Janusz Milanowski, et al.
Published: (2012-04-01) -
Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
by: Ting Zou, et al.
Published: (2023-11-01)